A new inactivated crown vaccine developed by China’s Kexing Corp. has been conditionally marketed, but the vaccine is rumored to have insufficient evidence of efficacy in the elderly population over 60 years of age, which could make the elderly, already a high-risk group, “white mice.
According to RIA Novosti, China has applied for conditional marketing of another Chinese communist virus vaccine, Kvisa, which is a single-dose vaccine that can be stored stably between 2°C and 8°C, making it easier to transport and store properly. The data shows that the efficacy of protection against severe disease is 90.07% after 28 days of single dose vaccination. Due to the questionable efficacy of the Kexin vaccine developed in China earlier, even in the age of 60 and above, the effectiveness was not significant, and the attitude towards Kvisa tended to be conservative.
China is now rumored to have a vaccine with conditional approval on the market, it is the new crown (CCP virus) vaccine “KvisaTM” by KangXinuo Biological Co. It is reported that the vaccine’s protective efficacy data has reached the World health Organization and the Chinese State Drug Administration’s guideline standards, and even obtained the approval of the military’s special-needs drugs issued by the Health Bureau of the Department of Logistics and Security as early as June 2020, which can be used by the Communist Party’s military for emergency purposes.
However, the State Drug Administration of China recently announced that another inactivated vaccine of Beijing Kexing Biotechnology Co. This may make the elderly, who are already at high risk, “white mice”.
According to foreign media reports, China’s State Drug Administration said at a press conference on the 19th, has conditionally approved the listing of two new Chinese crown (Chinese communist virus) virus vaccines, one is the inactivated vaccine by Sinopharm, and the other is the inactivated vaccine developed by Kexing, “KELAF”. And just after the announcement of the launch, Hong Kong received 1 million doses of “Kratom” on the 19th, and the vaccination program is expected to be officially launched on the 26th.
As the evidence of the efficacy of “Krelief” on groups over 60 years of age is not sufficient, the Hong Kong government has also made public the information provided by Kexing for clarification, but the information clearly shows that “Krelief” in the overseas phase III clinical data, groups over 60 years of age only account for about However, the information clearly shows that in the phase III clinical data from overseas, only about 5% of the study subjects were over 60 years old, so the evidence of the effectiveness of protection is not sufficient.
Recent Comments